Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Jae H. Park, MD, Isabelle Riviere, PhD, Devanjan S. Sikder, Vladimir P. Bermudez, Brigitte Senechal, Xiuyan Wang, PhD, Thomas H. Auchincloss, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, M. Lia Palomba, MD, Renier J. Brentjens, MD PhD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-143088

Published: 2020

Journal Articles

Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL

Jae H. Park, MD, Jessica Flynn, BS, Mithat Gonen, Yvette Bernal, MS, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, Xiuyan Wang, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2019) 134 (Supplement_1): 1348.

https://doi.org/10.1182/blood-2019-129343

Published: 2019

Journal Articles

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Blood (2018) 132 (Supplement 1): 959.

https://doi.org/10.1182/blood-2018-99-119717

Published: 2018

Journal Articles

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

Blood (2018) 132 (Supplement 1): 589.

https://doi.org/10.1182/blood-2018-99-110471

Published: 2018

Journal Articles

A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation

Jae H. Park, MD, Maria Lia Palomba, MD, Connie Lee Batlevi, MD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Brigitte Senechal, PhD, Richard R. Furman, MD, Yvette Bernal, MS, Malloury Hall, BA, John Pineda, RN, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, Renier J. Brentjens, MD PhD, Michel Sadelain, MD PhD

Blood (2018) 132 (Supplement 1): 224.

https://doi.org/10.1182/blood-2018-99-117737

Published: 2018

Journal Articles

Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells (HPCs) for Globin Gene Transfer in Patients with Sickle Cell Disease

Farid Boulad, MD, Tsiporah B. Shore, MD, Koen Van Besien, MD PhD, Danielle Guarneri, June Greenberg, RN, Caterina Minniti, MD, Sylvie wiener Fedus, Fabiana Perna, MD, Xiuyan Wang, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD, Patricia Shi, MD

Blood (2017) 130 (Supplement 1): 3531.

https://doi.org/10.1182/blood.V130.Suppl_1.3531.3531

Published: 2017

Journal Articles

Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM

Blood (2017) 130 (Supplement 1): 742.

https://doi.org/10.1182/blood.V130.Suppl_1.742.742

Published: 2017

Journal Articles

Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL

Mark Blaine Geyer, MD, Jae H. Park, MD, Isabelle Riviere, PhD, Brigitte Senechal, PharmD, PhD, Xiuyan Wang, PhD, Terence J. Purdon, Michel W. Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2016) 128 (22): 58.

https://doi.org/10.1182/blood.V128.22.58.58

Published: 2016

Journal Articles

Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL

Jae H Park, MD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Yvette Bernal, MS, Terence Purdon, Elizabeth Halton, RN, MS, ANP, Yongzeng Wang, PhD, Kevin J. Curran, MD, Craig S. Sauter, MD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2015) 126 (23): 682.

https://doi.org/10.1182/blood.V126.23.682.682

Published: 2015

Journal Articles

Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL

Blood (2015) 126 (23): 2533.

https://doi.org/10.1182/blood.V126.23.2533.2533

Published: 2015

Journal Articles

Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (B-NHL)

Craig S. Sauter, MD, Isabelle Riviere, PhD, Yvette J Bernal, MS, Xiuyan Wang, PhD, Terence J. Purdon, Sarah Yoo, Craig H Moskowitz, MD, Sergio Giralt, MD, Matthew J Matasar, MD MS, Kevin J. Curran, MD, Jae H Park, MD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2014) 124 (21): 677.

https://doi.org/10.1182/blood.V124.21.677.677

Published: 2014

Journal Articles

CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL

Jae H Park, MD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Yvette J Bernal, MS, Sarah Yoo, Terrence Purdon, Elizabeth Halton, RN, MS, ANP, Hilda Quintanilla, RN, MS, ANP, Kevin J. Curran, MD, Craig S. Sauter, MD, Marco L Davila, MD PhD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2014) 124 (21): 382.

https://doi.org/10.1182/blood.V124.21.382.382

Published: 2014

Journal Articles

Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy

Blood (2013) 122 (21): 69.

https://doi.org/10.1182/blood.V122.21.69.69

Published: 2013

Journal Articles

Phase I Trial Of Autologous CD19-Targeted CAR-Modified T Cells As Consolidation After Purine Analog-Based First-Line Therapy In Patients With Previously Untreated CLL

Jae H Park, MD, Isabelle Rivière, PhD, Xiuyan Wang, PhD, Jolanta Stefanski, Qing He, Oriana Borquez-Ojeda, Teresa Wasielewska, Clare Taylor, MSc, Jinrong Qu, Shirley Bartido, PhD, Yvette J Bernal, MS, Michel Sadelain, MD, PhD, Renier J Brentjens, MD, PhD

Blood (2013) 122 (21): 874.

https://doi.org/10.1182/blood.V122.21.874.874

Published: 2013

Journal Articles

First US Phase I Clinical Trial Of Globin Gene Transfer For The Treatment Of Beta-Thalassemia Major

Farid Boulad, MD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Shirley Bartido, PhD, Susan E. Prockop, MD, Rita Barone, M.D., Paolo Moi, MD, Aurelio Maggio, M.D., Michel Sadelain, MD, PhD

Blood (2013) 122 (21): 716.

https://doi.org/10.1182/blood.V122.21.716.716

Published: 2013

Journal Articles

Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL

Jae H. Park, MD, Isabelle Rivière, PhD, Xiuyan Wang, PhD, Jolanta Stefanski, Qing He, Clare Taylor, MSc, Malgorzata Olszewska, Teresa Wasielewska, Shirley Bartido, PhD, Marco L Davila, MD, PhD, Yvette Bernal, Nicole Lamanna, MD, Ariela Noy, MD, Michel Sadelain, MD, PhD, Renier J Brentjens, MD, PhD

Blood (2012) 120 (21): 1797.

https://doi.org/10.1182/blood.V120.21.1797.1797

Published: 2012

Journal Articles

Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19–28z CAR-Targeted T Cells

Marco L Davila, MD, PhD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Jae H. Park, MD, Jolanta Stefanski, Clare Taylor, MSc, Qing He, Malgorzata Olszewska, Teresa Wasielewska, Oriana Borquez-Ojeda, Jinrong Qu, Shirley Bartido, PhD, Joseph G. Jurcic, MD, Dan Douer, MD, Mark G. Frattini, MD, PhD, Michel Sadelain, MD, PhD, Renier J Brentjens, MD, PhD

Blood (2012) 120 (21): 3566.

https://doi.org/10.1182/blood.V120.21.3566.3566

Published: 2012

Journal Articles

CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL in Pediatric Patients Post HSCT

Kevin J. Curran, MD, Nancy A. Kernan, MD, Xiuyan Wang, PhD, Clare Taylor, MSc, Ekaterina Doubrovina, MD, PhD, Shirley Bartido, PhD, Michel Sadelain, MD, PhD, Richard J. O'Reilly, MD, Renier J Brentjens, MD, PhD, Isabelle Rivière, PhD

Blood (2012) 120 (21): 353.

https://doi.org/10.1182/blood.V120.21.353.353

Published: 2012

Journal Articles

Artificial Antigen Presenting Cells Expand NY-ESO-1 Antigen-Specific CD8+ T Cells From Patients with Melanoma

Marcela V. Maus, MD, PhD, Isabelle Riviere, PhD, Oriana Borquez-Ojeda, Xiuyan Wang, PhD, Jianda Yuan, MD, Taha Merghoub, PhD, Jason Plotkin, Richard J. O’Reilly, MD, Jedd D Wolchok, MD, PhD, Michel Sadelain, MD, PhD

Blood (2011) 118 (21): 4309.

https://doi.org/10.1182/blood.V118.21.4309.4309

Published: 2011

Journal Articles

Virus Specific T-Lymphocytes Genetically Modified to Target the CD19 Antigen Eradicates Systemic Lymphoma In Mice

Kevin J. Curran, MD, Clare Taylor, MSc, Ekaterina Doubrovina, MD, PhD, Xiuyan Wang, PhD, Richard J. O'Reilly, MD, Michel Sadelain, MD, PhD, Nancy A. Kernan, MD, Renier J. Brentjens, MD, PhD, Isabelle Riviere, PhD

Blood (2010) 116 (21): 2092.

https://doi.org/10.1182/blood.V116.21.2092.2092

Published: 2010

NARROW

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation

Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells (HPCs) for Globin Gene Transfer in Patients with Sickle Cell Disease

Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM

Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL

Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL

Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL

Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (B-NHL)

CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL

Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy

Phase I Trial Of Autologous CD19-Targeted CAR-Modified T Cells As Consolidation After Purine Analog-Based First-Line Therapy In Patients With Previously Untreated CLL

First US Phase I Clinical Trial Of Globin Gene Transfer For The Treatment Of Beta-Thalassemia Major

Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL

Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19–28z CAR-Targeted T Cells

CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL in Pediatric Patients Post HSCT

Artificial Antigen Presenting Cells Expand NY-ESO-1 Antigen-Specific CD8+ T Cells From Patients with Melanoma

Virus Specific T-Lymphocytes Genetically Modified to Target the CD19 Antigen Eradicates Systemic Lymphoma In Mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only